The Phase I SBI-087 dose escalation clinical trial is designed to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of a single dose of SBI-087 in patients with rheumatoid arthritis (RA). Preclinical research suggests that SBI-087, a fully humanized CD20-directed Small Modular ImmunoPharmaceutical, has enhanced potency in B-cell depletion in vivo compared with Rituxan.
This Phase I trial is designed to enroll patients who meet the criteria for RA with Functional Class I, II or III, and who have been diagnosed with RA more than six months prior to the study with onset of RA after the age of 16.
Peter Thompson, president, CEO and chairman of Trubion, said: “We believe SBI-087 and TRU-015 together will play an important role in improving patient care and helping us establish category leadership in autoimmune and inflammatory disease markets.”